Ofatumumab

CD20-directed Cytolytic Antibody — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Ofatumumab is a drug in the CD20-directed Cytolytic Antibody class catalogued in DrugCentral. It was first approved by the FDA in 2009. Its mechanism of action is classified as CD20-directed Antibody Interactions. DrugCentral lists 1 molecular target, including MS4A1. Recorded indications include Chronic lymphoid leukemia, disease, Relapsing multiple sclerosis and Secondary progressive multiple sclerosis.

• Drug class: CD20-directed Cytolytic Antibody.
• Mechanism of action: CD20-directed Antibody Interactions.
• Molecular targets: MS4A1 (1 listed in DrugCentral).
• Indications: Chronic lymphoid leukemia, disease, Relapsing multiple sclerosis and Secondary progressive multiple sclerosis.
• ATC code: L01FA02 (CD20 (Clusters of Differentiation 20) inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Chronic lymphoid leukemia, disease
• Relapsing multiple sclerosis
• Secondary progressive multiple sclerosis

Mechanism & targets

• Mechanism of action (MoA): CD20-directed Antibody Interactions
• Established pharmacologic class: CD20-directed Cytolytic Antibody

Molecular targets (1)

Target	Gene	Action	Activity
B-lymphocyte antigen CD20	MS4A1	other	Kd 9.92

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2021-03-23	PMDA	—	Novartis Pharma K.K.	Yes
2010-04-19	EMA	—	Novartis Europharm Ltd	Yes
2009-10-26	FDA	—	GLAXO GRP LTD

ATC classification

ATC code	Therapeutic hierarchy
L01FA02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › CD20 (Clusters of Differentiation 20) inhibitors
L04AG12	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Monoclonal antibodies

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: MS4A1
• FDA label: MS4A1
• HCSC label: MS4A1

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Multiple sclerosis relapse	842.3
Influenza like illness	533.9
Expanded disability status scale score increased	377.3
Multiple sclerosis	352.5
Accidental exposure to product	351.2
Pyrexia	320.3
Febrile neutropenia	318.2
Chills	305.7
Product storage error	223.7
Neutropenia	219.2
Device malfunction	218.2
Incorrect dose administered by device	211.0

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 679818-59-8
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ofatumumab used for?

DrugCentral lists the following indications for Ofatumumab: Chronic lymphoid leukemia, disease, Relapsing multiple sclerosis and Secondary progressive multiple sclerosis.

How does Ofatumumab work?

Ofatumumab is classified as CD20-directed Antibody Interactions; its molecular targets in DrugCentral include MS4A1.

When was Ofatumumab first approved?

Ofatumumab was first approved by the FDA in 2009.

What drug class does Ofatumumab belong to?

Ofatumumab is in the CD20-directed Cytolytic Antibody class.

Sources

• DrugCentral drug card 4951 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201836 — compound record and bioactivity
• DrugBank DB06650 — drug record
• FDA UNII M95KG522R0 — substance identity
• DailyMed: FDA labels for Ofatumumab — current prescribing information (label search)
• UniProt P11836 (MS4A1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.